[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605082":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":32,"locations":32,"responsibleParty":33,"collaborators":37,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":32,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":70,"whyStopped":32,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":32},{"fullName":5,"class":6},"University of the Punjab","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MSC-Derived Secretome","EXPERIMENTAL","MSC-derived secretome will be administered as intra-articular injections under ultrasound guidance to the affected knee. Injection will be given twice, each after 6 months. Each injection will consist of 2 mL of concentrated MSC-derived secretome.",[13],"Biological: MSC-Derived Secretome",{"label":15,"type":10,"description":16,"interventionNames":17},"MSC-Derived Secretome + Autologous PRGF","MSC-derived secretome combined with autologous plasma-rich in growth factors plasma (PRGF) will be administered as intra-articular injections under ultrasound guidance to the affected knee. Injections will be given twice, each after 6 months. Each injection will consist of 2 mL of concentrated MSC-derived secretome and 1 mL of autologous PRGF, totaling 3 mL per dose.",[18],"Biological: MSC-Derived Secretome + Autologous PRGF",[20,27],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","The secretome will be collected from cultured MSCs under sterile, GMP-compliant conditions and concentrated to retain bioactive molecules. It will be injected into the affected knee under ultrasound guidance.",[9],[25,26],"Conditioned Medium","MSC Secretome Therapy",{"type":21,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"MSC-derived secretome will be collected from mesenchymal stem cell cultures under sterile, GMP-compliant conditions. Autologous PRP will be prepared from the participant's own peripheral blood using a standardized single-spin centrifugation method and combined with 10% calcium chloride to activate growth factors. Both components will be mixed and administered into the affected joint under ultrasound guidance.",[15],[31],"MSC-Secretome\u002FPRGF Combined Therapy",null,{"type":34,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","Noreen Latief","Assistant Professor",[38],{"name":39,"class":40},"Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore.","UNKNOWN","100605082","early-phase-1-investigating-the-safety-and-regenerative-potential-of-msc-derived-secretome-combined-with-prgf-in-knee-osteoarthritis-100605082",false,"NCT07157891","Investigating the Safety and Regenerative Potential of MSC-Derived Secretome Combined With PRGF in Knee Osteoarthritis","PRGFSECKOA","Inclusion Criteria:\n\n* Following is the inclusion criteria for the enrolment of patients affected with damaged cartilage in this study:\n\n  * Diagnosed with primary OA in one or both knees based on American College of Rheumatology criteria\n  * Grade I and II Arthritis\n  * Joint pain ≥ 20mm measured by visual analogue scale\n  * Age ranges from 30-55 years of age\n  * BMI 27.12 ± 4.38\n  * Patients with no previous surgical interventions to lower limb\n  * Willing to participate in the study\n\nExclusion Criteria:\n\n* • Secondary OA due to trauma, infection, rheumatoid arthritis, congenital disease or other inflammatory disorders of the knee\n\n  * Diagnosed with a systemic autoimmune disorder, immunodeficiency or coagulation disorder\n  * Had history of malignancy\n  * History of allergy or allergic constitution\n  * Pregnant or breastfeeding women.","ALL","30 Years","55 Years",{"count":52,"type":53},25,"ESTIMATED","INTERVENTIONAL",[56],"EARLY_PHASE1","This Phase I\u002FII randomized clinical trial investigates the safety, feasibility, and early regenerative potential of intra-articular administration of mesenchymal stem cell (MSC)-derived secretome combined with Plasma Rich in Growth Factors (PRGF) in patients with knee osteoarthritis (KOA). The study aims to assess whether this cell-free, biologically enriched therapeutic combination can reduce pain, improve joint function, and promote cartilage repair.",[59,60,61],"Osteoarthritis (OA)","Knee Injury","Cartilage Degeneration",[63,64,65,66,67,68,69],"Mesenchymal Stem Cell Secretome","Plasma Rich in Growth Factors (PRGF)","Platelet-Rich Plasma (PRP)","Knee Osteoarthritis","Intra-articular Injection","Cell-free Therapy","Regenerative Medicine","NOT_YET_RECRUITING","2025-08-28",{"date":73,"type":74},"2025-09-05","ACTUAL",{"date":76,"type":53},"2025-12-10",{"date":78,"type":53},"2028-12-11",{"name":5,"class":6}]